<p>MaxCyte, Inc. (NASDAQ:MXCT - 获取免费报告) 在一月份的空头头寸大幅增长。截至 1 月 30 日，空头头寸总计为 3,881,689 股，比 1 月 15 日的 2,503,062 股增长了 55.1%。目前，该股票的 3.8% 股份被做空。根据平均每日交易量 1,116,399 股，空头头寸比率目前为 3.5 天。根据平均每日交易量 1,116,399 股，空头头寸比率目前为 3.5 天。目前，该股票的 3.8% 股份被做空。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>几位研究分析师最近对该公司发表了看法。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 MaxCyte 股票的 “卖出（e+）” 评级。华尔街 Zen 在 2 月 7 日的报告中将 MaxCyte 的评级从 “卖出” 上调至 “持有”。两位股票研究分析师给予该股票买入评级，两位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，MaxCyte 目前的平均评级为 “持有”，平均目标价格为 7.00 美元。</p>
<p><strong>阅读我们关于 MXCT 的最新股票报告</strong></p>
<h2>MaxCyte 价格表现</h2>
<p>NASDAQ:MXCT 的股票在周五交易中下跌 0.01 美元，报 0.72 美元。该公司交易了 1,262,423 股，相比其平均交易量 1,382,774 股。MaxCyte 的 12 个月低点为 0.68 美元，12 个月高点为 4.32 美元。该股票的市值为 7676 万美元，市盈率为-1.64，贝塔值为 1.21。该公司的 50 日移动平均价格为 1.28 美元，200 日移动平均价格为 1.48 美元。</p>
<p>MaxCyte (NASDAQ:MXCT - 获取免费报告) 最近在 11 月 12 日公布了其财报。该公司报告季度每股收益为（0.12 美元），低于分析师一致预期的（0.11 美元）0.01 美元。MaxCyte 的净利润率为-132.57%，股本回报率为-23.50%。该季度的收入为 641 万美元，而分析师预期为 837 万美元。整体来看，股票研究分析师预计 MaxCyte 在本年度将发布-0.42 美元的每股收益。</p>
<h2>机构投资者对 MaxCyte 的看法</h2>
<p>几家机构投资者最近对该股票的持仓进行了调整。Mirabella Financial Services LLP 在第二季度将其在 MaxCyte 的持股增加了 78.4%。Mirabella Financial Services LLP 目前拥有 660 万股该公司的股票，价值 1438.8 万美元，此前在上一季度又购买了 290 万股。Kennedy Capital Management LLC 在第三季度获得了 MaxCyte 的新头寸，价值 333 万美元。AXA S.A.在第二季度将其在 MaxCyte 的持仓增加了 123.2%。AXA S.A.目前拥有 2202378 股该公司的股票，价值 480.1 万美元，此前在上一季度又购买了 1215481 股。Jacobs Levy Equity Management Inc.在第四季度获得了 MaxCyte 的新股份，价值 159.4 万美元。最后，Willis Investment Counsel 在第三季度将其在 MaxCyte 的持仓增加了 126.8%。Willis Investment Counsel 目前拥有 862758 股该公司的股票，价值 136.3 万美元，此前在上一季度又购买了 482287 股。68.81% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>关于 MaxCyte</h2>
<p>(获取免费报告)</p>
<p>MaxCyte, Inc NASDAQ: MXCT 是一家临床阶段的细胞治疗平台公司，开发和商业化专有的流动电穿孔技术，以将大分子输送到活细胞中。该公司的仪器和耗材旨在支持细胞治疗的研究、临床前开发和临床规模生产，涵盖多种模式，包括工程化 T 细胞、自然杀伤（NK）细胞和诱导多能干细胞（iPSC）治疗。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 MaxCyte 更好</li>
<li>认为你错过了银？你错了。这就是原因。</li>
<li>你的银行账户不再安全</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>硅谷内部人士暗示 12 个月的 AI 警告</li>
<li>现在购买这只股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 MaxCyte 吗？</h2>
<p>在你考虑 MaxCyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 MaxCyte 并不在名单上。</p>
<p>虽然 MaxCyte 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MXCT

<p>MaxCyte, Inc.（纳斯达克代码：MXCT）在 1 月份的空头头寸显著增加，增长了 55.1%，达到 3,881,689 股。目前，该公司的股票中有 3.8% 被做空，基于平均交易量 1,116,399 股，覆盖天数比率为 3.5 天。分析师对该股票的评级不一，平均目标价格为 7.00 美元。MaxCyte 报告的季度每股收益为（0.12 美元），未达到预期，收入为 641 万美元，低于预期。机构投资者持有 68.81% 的股份</p>

<p>MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 3,881,689 shares, a growth of 55.1% from the January 15th total of 2,503,062 shares. Currently, 3.8% of the shares of the stock are short sold. Based on an average daily volume of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Based on an average daily volume of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Currently, 3.8% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>MaxCyte, Inc. (NASDAQ:MXCT - 获取免费报告) 在一月份的空头头寸大幅增长。截至 1 月 30 日，空头头寸总计为 3,881,689 股，比 1 月 15 日的 2,503,062 股增长了 55.1%。目前，该股票的 3.8% 股份被做空。根据平均每日交易量 1,116,399 股，空头头寸比率目前为 3.5 天。根据平均每日交易量 1,116,399 股，空头头寸比率目前为 3.5 天。目前，该股票的 3.8% 股份被做空。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of MaxCyte in a research report on Monday, December 29th. Wall Street Zen upgraded MaxCyte from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, February 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, MaxCyte presently has an average rating of &#34;Hold&#34; and an average target price of $7.00.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发表了看法。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 MaxCyte 股票的 “卖出（e+）” 评级。华尔街 Zen 在 2 月 7 日的报告中将 MaxCyte 的评级从 “卖出” 上调至 “持有”。两位股票研究分析师给予该股票买入评级，两位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，MaxCyte 目前的平均评级为 “持有”，平均目标价格为 7.00 美元。</p>
</div><p><strong>Read Our Latest Stock Report on MXCT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 MXCT 的最新股票报告</strong></p>
</div><h2>MaxCyte Price Performance</h2>
<div class="lb-trans"><h2>MaxCyte 价格表现</h2>
</div><p>Shares of NASDAQ:MXCT traded down $0.01 during trading on Friday, hitting $0.72. 1,262,423 shares of the company were exchanged, compared to its average volume of 1,382,774. MaxCyte has a 12-month low of $0.68 and a 12-month high of $4.32. The stock has a market capitalization of $76.76 million, a P/E ratio of -1.64 and a beta of 1.21. The firm's 50 day moving average price is $1.28 and its 200-day moving average price is $1.48.</p>
<div class="lb-trans"><p>NASDAQ:MXCT 的股票在周五交易中下跌 0.01 美元，报 0.72 美元。该公司交易了 1,262,423 股，相比其平均交易量 1,382,774 股。MaxCyte 的 12 个月低点为 0.68 美元，12 个月高点为 4.32 美元。该股票的市值为 7676 万美元，市盈率为-1.64，贝塔值为 1.21。该公司的 50 日移动平均价格为 1.28 美元，200 日移动平均价格为 1.48 美元。</p>
</div><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The business had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. As a group, equities research analysts anticipate that MaxCyte will post -0.42 EPS for the current year.</p>
<div class="lb-trans"><p>MaxCyte (NASDAQ:MXCT - 获取免费报告) 最近在 11 月 12 日公布了其财报。该公司报告季度每股收益为（0.12 美元），低于分析师一致预期的（0.11 美元）0.01 美元。MaxCyte 的净利润率为-132.57%，股本回报率为-23.50%。该季度的收入为 641 万美元，而分析师预期为 837 万美元。整体来看，股票研究分析师预计 MaxCyte 在本年度将发布-0.42 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On MaxCyte</h2>
<div class="lb-trans"><h2>机构投资者对 MaxCyte 的看法</h2>
</div><p>Several institutional investors have recently made changes to their positions in the stock. Mirabella Financial Services LLP increased its holdings in MaxCyte by 78.4% in the second quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company's stock valued at $14,388,000 after buying an additional 2,900,000 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in MaxCyte during the third quarter worth $3,330,000. AXA S.A. boosted its position in MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company's stock worth $4,801,000 after purchasing an additional 1,215,481 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in MaxCyte in the fourth quarter valued at $1,594,000. Finally, Willis Investment Counsel increased its position in shares of MaxCyte by 126.8% in the third quarter. Willis Investment Counsel now owns 862,758 shares of the company's stock valued at $1,363,000 after buying an additional 482,287 shares in the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近对该股票的持仓进行了调整。Mirabella Financial Services LLP 在第二季度将其在 MaxCyte 的持股增加了 78.4%。Mirabella Financial Services LLP 目前拥有 660 万股该公司的股票，价值 1438.8 万美元，此前在上一季度又购买了 290 万股。Kennedy Capital Management LLC 在第三季度获得了 MaxCyte 的新头寸，价值 333 万美元。AXA S.A.在第二季度将其在 MaxCyte 的持仓增加了 123.2%。AXA S.A.目前拥有 2202378 股该公司的股票，价值 480.1 万美元，此前在上一季度又购买了 1215481 股。Jacobs Levy Equity Management Inc.在第四季度获得了 MaxCyte 的新股份，价值 159.4 万美元。最后，Willis Investment Counsel 在第三季度将其在 MaxCyte 的持仓增加了 126.8%。Willis Investment Counsel 目前拥有 862758 股该公司的股票，价值 136.3 万美元，此前在上一季度又购买了 482287 股。68.81% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>About MaxCyte</h2>
<div class="lb-trans"><h2>关于 MaxCyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.</p>
<div class="lb-trans"><p>MaxCyte, Inc NASDAQ: MXCT 是一家临床阶段的细胞治疗平台公司，开发和商业化专有的流动电穿孔技术，以将大分子输送到活细胞中。该公司的仪器和耗材旨在支持细胞治疗的研究、临床前开发和临床规模生产，涵盖多种模式，包括工程化 T 细胞、自然杀伤（NK）细胞和诱导多能干细胞（iPSC）治疗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>Think You Missed Silver? You’re Wrong. Here’s Why.</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Silicon Valley insiders hint at 12-month AI warning</li>
<li>Buy This Stock Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 MaxCyte 更好</li>
<li>认为你错过了银？你错了。这就是原因。</li>
<li>你的银行账户不再安全</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>硅谷内部人士暗示 12 个月的 AI 警告</li>
<li>现在购买这只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 MaxCyte 吗？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MaxCyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 MaxCyte 并不在名单上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MaxCyte 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

MaxCyte, Inc.（纳斯达克股票代码：MXCT）的空头头寸在 1 月份上升了 55.1%